Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01775865 · ClinicalTrials.gov registry record · Phase 2
Targeting Inflammation to Treat Cardiovascular Aging
A Phase 2 study of Endothelial Dysfunction and Vascular Stiffness, sponsored by Gary L. Pierce.
- Completed
- Registry status
- Phase 2
- Development phase
- 59
- Enrollment target
- 1
- Study location
NCT01775865: Completed Phase 2 study of Endothelial Dysfunction and Vascular Stiffness, sponsored by Gary L. Pierce.
NCT01775865 is a Phase 2 study of Endothelial Dysfunction and Vascular Stiffness that has completed, run by Gary L. Pierce. The registered enrollment target is 59 participants, below the 91-participant average among 45 other Endothelial Dysfunction trials with a reported enrollment target (35% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01775865, a Phase 2 study of Endothelial Dysfunction and Vascular Stiffness, has completed, sponsored by Gary L. Pierce.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 59 participants
- Enrollment target
- 1
- Study location
Study Summary
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the United States with older age being a primary risk factor. The number of adults greater than age 65 years will almost double to 70 million by 2030, therefore identifying therapeutic strategies for treating or preventing age-related disorders in humans is of major biomedical importance. Cardiovascular aging, defined as a reduction in vascular and cardiac functions with normal aging, occurs even in the absence of CVD risk factors and overt CVD. A key feature of cardiovascular aging is stiffening of the large elastic central arteries such as the aorta. This is important because aortic stiffness directly contributes to clinical problems such as increased blood pressure, reduced blood flow to the heart muscle, and thickening of the heart muscle. Therefore, these clinical consequences are hypothesized to mediate a substantial proportion of the increase in CVD risk in older adults. However, effective drug treatments for aortic stiffness are not currently available and the biological reasons (mechanisms) involved in causing aortic stiffening remain undefined. In addition, the inability of smaller blood vessels to relax, impairment of the heart to relax during the filling phase of the heart cycle (i.e., diastole), and increased blood pressure variability, have all been linked to aortic stiffness. Furthermore, chronic low-grade inflammation with advancing age has been proposed to be a common mechanistic link (i.e., biological reason) between these reductions in cardiovascular function in older adults. Therefore, the investigators propose that inflammation could be a novel therapeutic target to treat cardiovascular aging in older adults. Our central hypothesis is that inflammation mediates the age-related deterioration in cardiovascular functions observed with advancing age through the development of oxidative stress (i.e., imbalance between damaging oxygen free radicals vs. protective antioxida
Primary Outcome
Aortic stiffness
Conditions Studied
Interventions
- DRUG Salsalate
- DRUG Placebo (for salsalate)
Study Locations (1)
Iowa
- University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2012-09 |
| Est. Completion | 2016-02 |
| Phase | Phase 2 |
What the finished NCT01775865 record still lists
NCT01775865 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 59 participants, a relatively small participant target, below the 91-participant average among 45 other Endothelial Dysfunction trials with a reported enrollment target (35% lower).
The record links to 3 conditions, with Endothelial Dysfunction appearing as the primary indexed condition, and to 2 interventions - of which Salsalate is the first listed.
NCT01775865 reports a single indexed study location in Iowa.
Frequently Asked Questions
What is clinical trial NCT01775865 about?
NCT01775865 is a clinical study titled "Targeting Inflammation to Treat Cardiovascular Aging". Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the United States with older age being a primary risk factor. The number of adults greater than age 65 years will almost double to 70 million by 2030, therefore identifying therapeutic strategies for treating or preventi...
What is the current status of trial NCT01775865?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 2012-09. Estimated completion is 2016-02.
What conditions does trial NCT01775865 study?
This clinical trial studies the following conditions: Endothelial Dysfunction, Vascular Stiffness, Diastolic Dysfunction.
What interventions are being tested in trial NCT01775865?
The interventions under investigation include: Salsalate (DRUG), Placebo (for salsalate) (DRUG).
Who is sponsoring clinical trial NCT01775865?
This trial is sponsored by Gary L. Pierce, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01775865 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endothelial Dysfunction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01775865's enrollment target sits among peer trials
59 20th of 45 higher than 26 of 45 other Endothelial Dysfunction trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Endothelial Dysfunction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ischemic Conditioning to Promote Microvascular Resiliency in Frail Individuals
RECRUITING · Phase 2
-
Atherosclerosis, Immune Mediated Inflammation and Hypoestrogenemia in Young Women
COMPLETED · Phase 2
-
Trial of Oral Glutamine on Mitochondrial Function in CKD
COMPLETED · Phase 2
-
Safety and Efficacy of Salsalate to Treat Endothelial Dysfunction in HIV-infected Adults
COMPLETED · Phase 2
-
MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes
RECRUITING · Phase 1
-
Effect of a Daily Supplement on Plasma PAI-1 Levels
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03801083 · 59 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
- NCT04332367 · 59 participants · Phase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
- NCT05489575 · 59 participants · NA
CPAP for the Treatment of Supine Hypertension
- NCT06721689 · 59 participants · Phase 1
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia